Additionally, in the Procomb study [43], Giuseppe et al. administered 134 men with lower urinary tract symptoms doses of 50 mg selenium and 5 mg lycopene for 2 years, but no significant statistical differences were observed in terms of the risk of prostate cancer or the mean changes of PSA between the two groups. This evidence concerns the gene KLK3 and prostate cancer.